Effect of flavonoids and CYP3A4 variants on midostaurin metabolism

被引:5
|
作者
Xu, Ren-ai [1 ,2 ]
Li, Qing-qing [2 ]
Gao, Nan-yong [2 ]
Wang, Jing [2 ]
Li, Xin-yue [2 ]
Ye, Feng [2 ]
Ni, Jin-huan [2 ]
Hu, Guo-xin [2 ,3 ]
Qian, Jian-chang [2 ,3 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325000, Peoples R China
[2] Wenzhou Med Univ, Inst Mol Toxicol & Pharmacol, Sch Pharmaceut Sci, Wenzhou, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Peoples R China
基金
中国国家自然科学基金;
关键词
Flavonoids; Midostaurin; Genetic polymorphism; Myricetin; Interaction; ACUTE MYELOID-LEUKEMIA; GENETIC POLYMORPHISMS; IN-VIVO; PHARMACOKINETICS; ANTIBACTERIAL; INHIBITION; MYRICETIN; APIGENIN;
D O I
10.1016/j.fct.2023.113669
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
The objective of this study was to determine the effect of flavonoids on midostaurin disposition considering co -administration and metabolic enzyme gene polymorphism. Enzymatic incubation assays were performed in vitro, while in vivo experiments were conducted in Sprague-Dawley rats. The analytes were determined via UPLC-MS/ MS. We found that myricetin was the most potent among the investigated 10 flavonoids in suppressing the metabolism of midostaurin, with an IC50 at a low mu M level. After co-administration of midostaurin and myricetin, the plasma concentration of midostaurin's primary metabolite CGP62221 was reduced corresponding to myr-icetin exposure. Furthermore, CYP3A4 homologous rat protein CYP3A2 was reduced significantly in the co -administration group. Thereafter, the kinetic parameters of 23 recombinant human CYP3A4 variants were determined using midostaurin. The relative intrinsic clearance varied from 269.63% in CYP3A4.29-8.95% in CYP3A4.17. In addition, the inhibitory potency of myricetin was substantially different for CYP3A4.29 and CYP3A4.17 compared with wild type, with IC50 values of 9.85 +/- 0.27 mu M and 90.99 +/- 16.13 mu M, respectively. Collectively, our data demonstrated that flavonoids, particularly myricetin, can inhibit the metabolism of mid-ostaurin. Additionally, CYP3A4 genetic polymorphism may contribute to stratification of midostaurin blood exposure.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Comparative drug metabolism by CYP3A4 and CYP3A5
    Huang, WL
    Lin, YS
    Dai, Y
    Totah, RA
    Calamia, JC
    Thummel, KE
    DRUG METABOLISM REVIEWS, 2003, 35 : 187 - 187
  • [22] The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population
    Hu, Xiaoxia
    Wang, Peng
    Zeng, Dali
    Hu, Guo-xin
    PEERJ, 2024, 12
  • [23] Involvement of CYP3A4 in the metabolism of bromperidol in vitro
    Sato, S
    Someya, T
    Shioiri, T
    Koitabashi, T
    Inoue, Y
    PHARMACOLOGY & TOXICOLOGY, 2000, 86 (03): : 145 - 148
  • [24] Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids
    Kondza, Martin
    Bojic, Mirza
    Tomic, Ivona
    Males, Zeljan
    Rezic, Valentina
    Cavar, Ivan
    MOLECULES, 2021, 26 (10):
  • [25] Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and pharmacodynamics of zolpidem
    Seonghae Yoon
    Seongmee Jeong
    Eben Jung
    Ki Soon Kim
    Inseung Jeon
    Yujin Lee
    Joo-Youn Cho
    Woo-Yong Oh
    Jae-Yong Chung
    Scientific Reports, 11
  • [26] Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and pharmacodynamics of zolpidem
    Yoon, Seonghae
    Jeong, Seongmee
    Jung, Eben
    Kim, Ki Soon
    Jeon, Inseung
    Lee, Yujin
    Cho, Joo-Youn
    Oh, Woo-Yong
    Chung, Jae-Yong
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [27] Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone
    Lee, Lucy
    Thoolen, Martin
    Ma, Jiyuan
    Kaushik, Diksha
    Golden, Lee
    Kong, Ronald
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (12): : 1283 - 1290
  • [28] Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
    A. B. Sanchez Spitman
    D. J. A. R. Moes
    H. Gelderblom
    V. O. Dezentje
    J.J. Swen
    H. J. Guchelaar
    European Journal of Clinical Pharmacology, 2017, 73 : 1589 - 1598
  • [29] The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline
    Hu, Xiaoqin
    Ni, Jinhuan
    Gao, Nanyong
    Ye, Zhize
    Hu, Guoxin
    Cai, Jianping
    Qian, Jianchang
    CHEMICO-BIOLOGICAL INTERACTIONS, 2022, 366
  • [30] Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
    Spitman, A. B. Sanchez
    Moes, D. J. A. R.
    Gelderblom, H.
    Dezentje, V. O.
    Swen, J. J.
    Guchelaar, H. J.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (12) : 1589 - 1598